[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-dysplasia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,44,80,111,136,163,207,228,256,286,308,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100443232","leveraging-methylated-dna-markers-mdms-in-the-detection-of-endometrial-cancer-ovarian-cancer-and-cervical-cancer-100443232",false,"NCT05051722","Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study","ECHO","Inclusion Criteria for Cohort 1:\n\nPatients will be ≥45 years of age and meet one of the following criteria:\n\n* Abnormal uterine bleeding\n* Postmenopausal bleeding\n\nOR\n\nPatients ages 18 - 44 years of age and meet these criteria\n\n* Abnormal uterine bleeding\n* One risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use)\n\nExclusion Criteria for Cohort 1:\n\n* Prior hysterectomy\n* Current known pregnancy diagnosis\n* Any prior pelvic or vaginal radiotherapy\n* Any prior cancer (except basal cell skin cancer) within the past 5 years\n* Chemotherapy within the past 5 years\n* Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia\n* Current biopsy-proven endometrial cancer or endometrial hyperplasia\n* Current biopsy-proven benign endometrial polyp\n* Endometrial biopsy\u002Fsampling within the preceding 1 month showing benign endometrium\n\nInclusion Criteria for Cohort 2:\n\nPatients will be ≥18 years of age and meet at least one of the following criteria:\n\n* Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D\\&C, hysteroscopic resection\n* Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D\\&C, hysteroscopic resection, etc)\n\nExclusion Criteria for Cohort 2:\n\n* Undergoing surgical procedure for recurrent or metastatic EC\n* Received preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis\n* Prior hysterectomy\n* Current known pregnancy diagnosis\n* Prior or current biopsy-proven cervical cancer\n* Presence of concomitant biopsy-proven cervical dysplasia\n* Any prior pelvic or vaginal radiotherapy\n* Any prior cancer (except basal cell skin cancer) within the past 5 years\n* Chemotherapy within the past 5 years\n* Prior intervention or surgery with intent to completely remove the target pathology\n\nInclusion Criteria for Cohort 3:\n\nPatients will be ≥18 years of age, have a cervix and meet at least one of the following criteria:\n\n* History of current abnormal cervical\u002Fendocervical Pap test for which the patient is presenting for colposcopy\n* Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated\n* Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)\n\nExclusion Criteria for Cohort 3:\n\n* History of pelvic or vaginal radiotherapy\n* Prior total hysterectomy (cervix removed) for any indication\n* Current known pregnancy diagnosis\n* Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin\n* Any prior cancer (except basal cell skin cancer) within the past 5 years\n* Chemotherapy within the past 5 years\n* Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass\n* Prior intervention or surgery with intent to completely remove the target pathology for the current lesion \u002F diagnosis during the current episode\n\nInclusion Criteria for Cohort 4:\n\nPatients will be ≥45 years of age and should meet at least one of the following criteria:\n\n* Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and\u002For clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps.\n* Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.\n\nExclusion Criteria for Cohort 4:\n\n* Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis\n* Any surgery within the past 3 months\n* Prior hysterectomy\n* Current known pregnancy diagnosis\n* Prior or current biopsy-proven gynecologic cancer\n* Current biopsy-proven AEH\u002FEIN, cervical, vaginal, or vulvar dysplasia\n* Prior pelvic or vaginal radiotherapy\n* Any prior cancer (except basal cell skin cancer) within the past 5 years\n* Chemotherapy within the past 5 years\n* Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis\n* Prior intervention or surgery with intent to completely remove the target pathology for the current lesion \u002F diagnosis during the current episode\n\nInclusion Criteria for Cohort 5:\n\nPatients with a uterus will be ≥45 years of age and should meet the following criteria:\n\n* Presenting for GYN wellness exam, ± Pap test\n* No change in medical conditions, new diagnoses, or new medications within the past 6 months\n\nExclusion Criteria for Cohort 5:\n\n* Pap test or cervical biopsy within the past 1 month\n* Endometrial biopsy or office hysteroscopy within the past 1 month\n* Any surgery within the past 3 months\n* Prior hysterectomy\n* Current known pregnancy diagnosis\n* Prior or current biopsy-proven gynecologic cancer\n* Current biopsy-proven AEH\u002FEIN, cervical, vaginal, or vulvar dysplasia\n* Prior pelvic or vaginal radiotherapy\n* Any prior cancer (except basal cell skin cancer) within the past 5 years\n* Chemotherapy within the past 5 years\n* Criteria met for inclusion in any of the other study cohorts\n\nInclusion Criteria for Cohort 6:\n\nPatients ≥50 years of age and:\n\n* Postmenopausal\n* At least 1 intact ovary\n* Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer)\n* Planned surgery for the adnexal mass\n* For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube\\* (without prior tubal ligation\u002Focclusion)\n\nExclusion criteria for Cohort 6:\n\n* Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn)\n* Chemotherapy for cancer treatment within the past 5 years prior to collection\n* Clinically suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection\n* Surgical candidates for recurrent ovarian cancer\n* History of pelvic or vaginal radiation therapy\n* Known current synchronous endometrial cancer or hyperplasia\n* Known current cervical, vaginal, or vulvar dysplasia\n\nInclusion criteria for Cohort 7:\n\nWomen will be ≥18 years of age and meet the following criteria:\n\n* Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any\u002Fall of the following: imaging showing adnexal and\u002For abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology\n* Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy\n* At least one intact ovary\n* For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube\\* (without prior tubal ligation\u002Focclusion)\n\nExclusion criteria for Cohort 7:\n\n* Patients with recurrent OC\n* Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years\n* Chemotherapy for cancer treatment within the past 5 years prior to collection\n* History of pelvic or vaginal radiation therapy\n* Known current synchronous endometrial cancer or hyperplasia\n* Known current cervical, vaginal, or vulvar dysplasia\n* Current known pregnancy diagnosis","FEMALE","18 Years",{"count":20,"type":21},3110,"ESTIMATED","OBSERVATIONAL","The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and\u002For plasma.\n\nThis proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.",[25,26,27,28,29,30],"Endometrial Cancer","Cervical Cancer","Atypical Endometrial Hyperplasia","Cervical Dysplasia","Adnexal Mass","Ovarian Cancer","RECRUITING","2026-04-16",{"date":34,"type":35},"2026-04-17","ACTUAL",{"date":37,"type":35},"2021-08-03",{"date":39,"type":21},"2027-06-30",{"name":41,"class":42},"Mayo Clinic","OTHER",24,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100379879","self-sampling-for-non-attenders-to-cervical-cancer-screening-100379879","NCT04226313","Self-sampling for Non-attenders to Cervical Cancer Screening","Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection","KOPRETINA","Inclusion Criteria:\n\n* Women with age 30-65 years; for arm A women \\> 65 years are allowed\n* Women live in the Czech Republic.\n* Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).\n* Women with completed informed consent.\n* Women capable of self-sampling of cervicovaginal swab.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Women with no sexual intercourse experience.\n* Women after hysterectomy including cervix.",true,"30 Years","65 Years",{"count":56,"type":21},15000,"INTERVENTIONAL",[59],"NA","The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.",[26,28,62],"Human Papillomavirus Infection",[64,65,66,67,68,69],"human papillomavirus","HPV","self-sampling","cervicovaginal swab","cervical cancer screening","non-attendance","2026-03-19",{"date":72,"type":35},"2026-03-23",{"date":74,"type":35},"2019-09-23",{"date":76,"type":21},"2026-12-01",{"name":78,"class":42},"The Institute of Molecular and Translational Medicine, Czech Republic",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":57,"phases":90,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100625933","early-phase-1-effectiveness-of-a-vaginal-gel-on-cin12-regression-and-hpv-clearance-100625933","NCT07429071","Effectiveness of a Vaginal Gel on CIN1\u002F2 Regression and HPV Clearance.","Effectiveness of a Non-Invasive Treatment Using a Vaginal Gel in Promoting HPV Clearance and Regression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Positive HPV test\n* Underwent colposcopy with subsequent histopathological findings of CIN1 or CIN2\n* Allocated to a 'watchful waiting' management strategy.\n* Understand Danish, written and orally.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unexplained bleeding\n* Immunosuppressive\u002Fmodulatory diseases or treatment\n* Cancer or cancer related diseases","50 Years",{"count":89,"type":21},70,[91],"EARLY_PHASE1","The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel promotes regression of CIN1\u002FCIN2 and facilitates HPV clearance in women aged 30-50 years diagnosed with CIN1 or CIN2 and HPV. In addition, the study will assess patient satisfaction, treatment compliance and characterize the vaginal microbiome.\n\nThe primary outcomes therefore is:\n\n* the regression of the cervical dysplasia from baseline to the follow-up (6 months), which will be assessed through either liquid-based cytology and\u002For histopathology (biopsy).\n* HPV clearance from baseline to follow-up (6 months)\n\nIn this randomized controlled study, eligible participants will be randomized 1:1 into two groups:\n\n1. Intervention group: Women (n=35) will apply a CV-based vaginal gel (Papilocare®) daily for 21 days for 3 months. Afterward, the gel should be used every other day for an additional 3 months. Every month includes a 7-day break due to menstruation (28 days cycle).\n2. Control group; Women (n=35) will follow the conventional \"wait and see\" approach.",[94,28,95,96,97],"Womens Health","Cervical Intraepithelial Neoplasia (CIN)","Non-invasive Treatment","Human Papilloma Virus (HPV)",[94,28,95,99,100],"Human Papillomavirus (HPV)","Non-Invasive Treatments","NOT_YET_RECRUITING","2026-03-02",{"date":104,"type":35},"2026-03-04",{"date":106,"type":21},"2026-03",{"date":108,"type":21},"2026-09",{"name":110,"class":42},"University of Aarhus",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":118,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":79},"100498769","role-of-liquid-biopsies-in-hpv-associated-cancer-treatment-monitoring-100498769","NCT05774561","Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring","Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases","Inclusion Criteria:\n\nWomen diagnosed with CC\u002FHSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria are set.","ALL","99 Years",{"count":121,"type":21},480,"This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.",[26,28,124,62],"Oropharyngeal Cancer",[64,65,126,67,127,128],"liquid biopsies","cervical cancer","oropharyngeal cancer","2026-02-10",{"date":131,"type":35},"2026-02-12",{"date":133,"type":35},"2022-06-01",{"date":76,"type":21},{"name":78,"class":42},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":52,"sex":17,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":57,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":79},"100611410","the-mother-daughter-project-merck-4-100611410","NCT07240220","The Mother-Daughter Project: Merck-4","The Mother-Daughter Project: Inclusion of Difficult-to-reach Kenyan Families, and Studies of Factors Influencing the Immune Response to HPV Vaccination (Merck-4)","Merck-4","Kenyan Adult Women\n\nInclusion Criteria:\n\n* ages 25 through 49 years\n* able\u002Fwilling to sign informed consent\n* willing to participate in the community meetings\n\nExclusion Criteria:\n\n• pregnant\n\nKenyan Girls\n\nInclusion Criteria:\n\n* ages 9 through 14 years\n* have mother that is able\u002Fwilling to sign informed consent for vaccination\n* can return for the second HPV vaccine dose in 6 - 12 months\n\nExclusion Criteria:\n\n• girls who are not willing or unable to return for the second HPV vaccine dose","9 Years","49 Years",{"count":147,"type":21},2500,[59],"This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children.\n\nThis project specifically aims to collect additional data on the ability for HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women, to investigate and identify barriers leading to non-participation in previous MDP efforts, and to examine factors associated with the immune response to HPV vaccination among rural Kenyan girls.",[28],[152,68,153],"cervical dysplasia","HPV infection","2026-01-14",{"date":156,"type":35},"2026-01-15",{"date":158,"type":21},"2026-02-01",{"date":160,"type":21},"2028-08-01",{"name":162,"class":42},"Indiana University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":57,"phases":175,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":206},"100370084","phase-2-artesunate-vaginal-inserts-for-the-treatment-of-cervical-intraepithelial-neoplasia-cin23-100370084","NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","25 Years","100 Years",{"count":174,"type":21},78,[176],"PHASE2","This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[179,180,181,28,182],"CIN 2\u002F3","HPV Infection","Pre-Cancerous Dysplasia","HPV Related Disease",[184,185,186,187,188,189,190,191,192,193,194,195],"treatment study","cancer prevention","non-surgical","HPV related disease","CIN","topical treatment","vaginal inserts","artesunate","artemisinin","non-invasive","high risk HPV","vaginal suppository","2025-09-29",{"date":198,"type":35},"2025-10-02",{"date":200,"type":35},"2020-09-09",{"date":202,"type":21},"2026-12-31",{"name":204,"class":205},"Frantz Viral Therapeutics, LLC","INDUSTRY",7,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":57,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":79},"100485827","circulating-human-papilloma-virus-hpv-dna-for-the-screening-and-surveillance-of-gynecologic-cancers-100485827","NCT05606133","Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers","Implementation of Circulating HPV DNA for the Screening and Surveillance of HPV-related Gynecologic Cancers","Inclusion Criteria:\n\nAll patients above age 18, with biopsy proven HPV-related high-grade cervical dysplasia or invasive cervical cancer will be included.\n\nExclusion Criteria:\n\nPersons who do not meet the above inclusion criteria.",{"count":215,"type":21},100,[59],"Human papilloma virus-related gynecologic malignancies affect over 20,000 women in the United States, and over half a million women globally each year. In addition, approximately 200,000 women are diagnosed with high-grade cervical dysplasia, a pre-cancerous tumor. There is no currently available serum biomarker for these tumors, and surveillance and diagnosis in these patients often requires invasive testing and procedures. The ability to diagnose and monitor for these cancers with a simple blood draw would have a significant impact both here in the US and abroad.\n\nIn order to detect circulating tumor-specific HPV DNA, the investigators will collaborate with the molecular diagnostics company, Naveris. Naveris has designed a blood test that utilizes digital droplet polymerase chain reactions (PCR) in order to quantify fragments of tumor-specific DNA that the investigators believe is shed by HPV-associated cancer cells in the blood.\n\nIn this pilot study, the investigators will first test whether the quantification of plasma cell-free HPV DNA can distinguish pre-invasive from invasive cervical cancers.",[28,26],"2025-09-18",{"date":221,"type":35},"2025-09-23",{"date":223,"type":35},"2022-08-10",{"date":225,"type":21},"2026-08-10",{"name":227,"class":42},"Northwell Health",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":52,"sex":17,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":57,"phases":238,"briefSummary":239,"conditions":240,"keywords":246,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":79},"100290490","screening-for-anal-cancer-in-women-with-high-grade-vulvar-dysplasia-or-vulvar-cancer-100290490","NCT03061435","Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.","Vulvar-AIN","Inclusion Criteria:\n\n* Women age ≥ 40\n* Previous diagnosis of VIN 2\u002F3 or vulvar\n\nExclusion Criteria:\n\n* Women with a previous diagnosis of cancer aside from basal cell carcinoma of the skin, cervical cancer, or vulvar cancer\n* Women who are HIV positive\n* Women currently taking immunosuppressant medication\n* Women who have had a previous hysterectomy","40 Years",{"count":237,"type":21},110,[59],"Almost half of all women will develop an HPV infection in their lifetime. While most infections are naturally asymptomatic or cleared by the immune system, some persist and can lead to the development of cervical, vulvar, or anal lesions and eventually cancer. Screening regimens for these lesions are currently only in place for the cervix through regular Pap tests. These Pap tests usually involve an examination of the vulva -however, no screening procedures exist for anal cancer for women. Several studies have suggested that women with existing gynecological lesions are more likely to develop anal lesions and anal cancer. Here the investigators propose a multi-center study which seeks to screen for and treat anal cancer in women over the age of 40 with vulvar lesions and a stable immune system. The investigators will achieve this through performing anal Pap smears on eligible women and conducting High Resolution Anoscopy (HRA) and appropriate treatment procedures on those with abnormal anal cells. With enough evidence, there may be an indication to establish regular anal cancer screening measures in this potentially underserved population.\n\nHypothesis: The investigators hypothesize that at least 40% of women with vulvar cancer or VIN2\u002F3 will have abnormal anal cytology. 35% of the population will be hrHPV DNA positive and 11% will additionally have AIN2\u002F3. This prospective study may lay the groundwork for routine anal screening regimens in Ontario and help shift health policy to treat this population.",[241,26,242,28,243,244,245],"Vulvar Cancer","Vulvar Dysplasia","Anal Cancer","Anal Dysplasia","HPV-Related Anal Squamous Cell Carcinoma",[241,26,242,28,243,244,65],"2025-05-13",{"date":249,"type":35},"2025-05-16",{"date":251,"type":35},"2021-02-01",{"date":253,"type":21},"2026-01-01",{"name":255,"class":42},"Dr. Danielle Vicus",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":263,"enrollmentInfo":264,"targetDuration":266,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100522122","sexual-function-and-quality-of-life-after-leep-a-prospective-multi-center-study-100522122","NCT06078514","Sexual Function and Quality of Life After LEEP: a Prospective Multi-Center Study","SEQUEL","Inclusion Criteria:\n\n* Age 18 to 70 years\n* First colposcopy visit (in 24 months, if previous colposcopies)\n* Referral for cytological changes or repeated HPV positivity\n* No previous LEEP or other operations affecting the length of cervix\n* Not pregnant at the time of colposcopy\u002FLEEP\n* Sexually active\n* Capable of understanding the study protocol - informed consent given\n* Fluent in Finnish\n\nExclusion Criteria:\n\n* Age less than 18 or more than 70 years\n* Previous colposcopy within 24 months\n* Referral for other reason, e.g. vulvar lesion\n* Previous LEEP or other operation affecting the length of cervix\n* Pregnant at the time of colposcopy\u002FLEEP\n* Sexually inactive\n* Unable to understand the study protocol - no informed consent\n* Difficulties in understanding Finnish","70 Years",{"count":265,"type":21},1000,"5 Years","The goal of this prospective study is to investigate the sexual function and quality of life of women undergoing loop electrosurgical excision procedure (LEEP) due to HPV-related cervical lesion.\n\nThe main question it aims to answer are:\n\n* Whether LEEP affects the sexual function of women in comparison to untreated women, and\n* Whether LEEP affects the health-related quality of life of women in comparison to untreated women\n\nParticipants are asked to complete web based an international validated self-report questionnaire on sexual function issues, the Female Sexual Function Index (FSFI), and a validated quality of life -questionnaire 15D at the time of first colposcopy appointment and six and 24 months, 3 years and 5 years after index visit (LEEP or first colposcopy in control group). Relevant additional background information is also collected via questionnaire and from patient files.\n\nResearchers will compare women with LEEP and those with only colposcopy visits to see any differences between self-reported sexual function (FSFI scores) or health-related quality of life (15D scores) both short and long-term.",[28],[270,271,272,273,274,275],"Colposcopy","LEEP","Cervical dysplasia","HSIL","Sexual function index","Health-related quality of life","2025-03-19",{"date":278,"type":35},"2025-03-20",{"date":280,"type":35},"2024-05-02",{"date":282,"type":21},"2030-12",{"name":284,"class":42},"Tampere University Hospital",5,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":52,"sex":17,"minAge":171,"maxAge":263,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":79},"100488483","vaginal-microbiome-and-hpv-pre-malignant-and-cervical-dysplasia-100488483","NCT05640700","Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia","Assessing Personalized Vaginal Microbiome Contributions to HPV-driven Pre-malignant and Malignant Cervical Cancer","Inclusion Criteria:\n\n* Age 25-70\n* Attended the clinic for a Pap smear or colposcopy\n\nExclusion Criteria:\n\n* Patient does not approve sample collection\n* Usage of antibiotics in the month prior to clinic visit\n* Usage of any vaginal preparation or medication in the week prior to sample collection (anti-fungal, spermicides, lubricant etc.)\n* Menstruation\n* Pregnancy",{"count":294,"type":21},90,"In this study, the investigators will prospectively collect, analyze and integrate information regarding vaginal microbiome composition and HPV presence in women with cervical pathologies (high-grade CIN and CC) and controls, to construct a large dataset from patients with pre-cancerous cervical lesions and healthy women, to evaluate the personalized contribution of the vaginal microbiome to the CIN-CC sequence.",[297,298,299,28],"Human Papilloma Virus","Vaginal Flora Imbalance","Cancer Cervix Uterus","2025-03-15",{"date":276,"type":35},{"date":303,"type":35},"2022-11-09",{"date":305,"type":21},"2025-12-30",{"name":307,"class":42},"Hadassah Medical Organization",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":57,"phases":318,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":79},"100469318","large-loop-excision-of-the-transformation-zone-during-follicular-vs-luteal-phase-of-the-menstrual-cycle-lletz-mc-100469318","NCT05391243","Large Loop Excision of the Transformation Zone During Follicular Vs. Luteal Phase of the Menstrual Cycle (LLETZ-MC)","Performance of Large Loop Excision of the Transformation Zone (LLETZ) in Women with Cervical Dysplasia in the Follicular Phase Versus the Luteal Phase of the Menstrual Cycle: a Prospective Randomized Trial","LLETZ-MC","Inclusion Criteria:\n\n* Written consent\n* Regular menstrual cycle, defined as an interval between 21 and 35 days and a bleeding duration between 3 and 10 days during the last 3 months\n* Colposcopy performed preoperatively\n* Histologically (by previously performed colposcopy) confirmed dysplasia (CIN 1, CIN 2 or CIN 3)\n* Suspicion of low-grade or high-grade squamous intraepithelial lesion based on Papanicolaou smear with inconclusive colposcopy and need for surgical workup to exclude lesions\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Pregnant patients\n* Patients with insufficient knowledge of the German language\n* Pre-existing oncological diseases\n* Blood coagulation disorders\n* Taking blood thinning substances\n* Use of a hormonal intrauterine device (e.g. Mirena);\n* Use of a progesterone pill or progesterone injectate;\n* Use of long cycle contraceptive (no monthly bleeding).",{"count":317,"type":21},152,[59],"Cervical cancer is one of the most common cancers in women and one of the leading causes of death in women worldwide. Pre-cancerous lesions (dysplasias) are detected by the preventive smear test at the gynecologist and can thus contribute to a 100% chance of cure if they are clarified by a colposcopic examination as part of the dysplasia consultation and dysplastic lesions are then surgically removed if necessary (conization).\n\nThere are few data in the literature on the influence of the menstrual cycle on the bleeding pattern during and after conization. Hormonal variations during the menstrual cycle affect both the extent of blood flow to reproductive organs and hemostasis. In the follicular phase, there is a decrease in local blood flow in the uterus and pelvic organs and an increase in coagulability. Conversely, in the luteal phase there is an increase in local blood supply and a decrease in coagulability. Therefore, it seems reasonable to perform conization in the follicular phase to possibly reduce the extent and incidence of bleeding and bleeding complications. This assumption is supported by clinical observations. For example, there is evidence from other specialties that selection of the timing of surgery, taking into account the menstrual phase, may influence the risk of bleeding. Another factor of interest in menstruation-based surgical planning is psychological vulnerability, which may also vary with the menstrual cycle. Until now, consideration of the menstrual cycle in surgical planning for conization has not been standard practice and there is no recommendation in this regard in the current S3 guideline of the German Society of Gynecology and Obstetrics.\n\nTherefore, this study now aims to answer the question under prospective randomized conditions whether LLETZ conization performed during the follicular phase results in lower blood loss and higher patient satisfaction and lower anxiety scores compared to LLETZ conization performed during the luteal phase.",[28],[152,322,271,323,324],"LLETZ","conization","menstrual cycle","2025-01-29",{"date":327,"type":35},"2025-01-31",{"date":329,"type":21},"2025-03",{"date":331,"type":21},"2026-12",{"name":333,"class":42},"Ruhr University of Bochum",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":57,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":79},"100421833","comparison-of-lletz-versus-leep-for-the-treatment-of-cervical-dysplasia-100421833","NCT04772937","Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia","Comparison of Two Surgical Approaches in the Treatment of Cervical Dysplasia: Complete Removal of the Transformation Zone (LLETZ) Versus Isolated Resection of the Colposcopically Visible Lesion (LEEP)","Inclusion Criteria:\n\n* Histologically confirmed High Grade Squamous Intraepithelial Lesion (HSIL)\n* Colposcopically visible lesion\n* No therapy of the disease so far\n\nExclusion Criteria:\n\n* Pregnancy of the patient at\u002Fafter inclusion in the study; pregnancy after conization and before the control after 6 months is possible and does not lead to exclusion from the study.\n* Taking immunosuppressive drugs (incl. glucocorticoids)\n* Known HIV positivity\n* Malignant disease requiring treatment\n* Unsatisfactory colposcopy",{"count":342,"type":21},206,[59],"Cervical dysplasia is the precursor of cervical cancer. LEEP and LLETZ are standard surgical procedures to treat cervical dysplasia. There is no direct head-to-head comparison between LEEP and LLETZ in the literature regarding oncologic safety, for which complete resection of the dysplastic lesion (so-called 'in-sano resection') is the most appropriate postoperative surrogate parameter. Further clinical studies are therefore useful to optimize surgical therapy for cervical dysplasia.\n\nThe primary objective of the present study is to compare LLETZ (resection of the dysplastic lesion including the transformation zone) with targeted resection of the colposcopically conspicuous lesion only (LEEP) and to compare it with regard to oncological safety (defined as non-in-sano rate).",[28],[152,323,347,127,322,271],"surgery",{"date":349,"type":35},"2025-01-30",{"date":351,"type":35},"2021-06-07",{"date":353,"type":21},"2025-11",{"name":333,"class":42}]